Abstract

BackgroundAbout 85% of patients with schizophrenia have cognitive impairments, executive functions being particularly affected. Executive dysfunctions are important predictors of functional outcomes. Unlike psychotic symptoms, cognitive deficits do not improve during periods of remission and change only minimally with antipsychotic medications. Thus, effective interventions aimed at improving executive functions in this population are needed.One of the most validated interventions for executive dysfunction is Goal Management Training (GMT). GMT is a compensatory intervention that relies on metacognitive strategies for improving participants’ ability to organize and achieve goals in everyday life. GMT has received empirical support in studies of other populations, such as people with neurological conditions and in healthy elderly. To our knowledge no previous studies have investigated the effect of group-based GMT in patients with schizophrenia spectrum disorders or with high risk of schizophrenia. Thus, this is the main objective of the study. Baseline characteristis and preliminary results from the first patients will be presented.MethodsParticipants (16–67 years, males and females, IQ >70) with executive dysfunction, will be recruited among patients referred for treatment at Innlandet Hospital Trust in Norway from 2017 to 2020. The study aims to include patients treated for psychotic disorder for less than 5 years and new patients who either have symptoms that meet the DSM-IV criteria for a diagnosis of broad schizophrenia spectrum disorder or who are considered at high risk of psychosis. We aim to recruit one hundred participants for the current randomized controlled trial (RCT), with efficacy of GMT (n = 50) being compared with results of subjects in a wait-list condition (WL, n = 50).Measurements include self-report of executive function, emotional health, and social- and everyday function. Informant reports of executive function will also be collected. Furthermore, neuropsychological tests designed specifically to measure areas of executive function will be utilized, as well as role-playing tasks thought to have good ecological validity. Symptoms of psychosis will also be assessed. GMT will be administered in 9 (twice weekly) x 2 hour sessions in accordance with the GMT research protocol.A general linear model with repeated measures analysis of variance (RM ANOVA) will be used to examine differential group treatment effects. A 2 x 3 mixed-design will be applied, with Group (GMT, WL) as between-subjects factor, and Session (baseline [T1], post-intervention [T2], and 6 months follow-up [T3]) as within-subjects factor. Interpretation of the strength of experimental effects will be provided with effect size statistics.ResultsBaseline characteristics and preliminary results from the first participants will be presented.DiscussionBased on findings from previous GMT-studies, we hypothesize that post-intervention changes will be reflected in improved scores on self-reported and/or objective measures of executive functions (particularly in the areas of planning and attentional control) compared to patients in WL. We also expect that GMT participants will improve their goal attainment in everyday life and social functioning after the intervention. Additionally, we expect post-intervention changes to be reflected in improved scores on measures of emotional health.

Highlights

  • Previous literature comparing cognitive functioning between bipolar disorder (BD) and schizophrenia (Sch), focused on remitted patients with BD and clinically stable patients with Sch; and suggested milder cognitive impairment in BD in comparison to Sch

  • This study provides evidence for a growing literature which suggests that neurocognitive deficits may be markers of susceptibility for SMI development

  • Several domains of cognitive functioning were compared among patients with BD who had a history of psychosis [32 with a current psychotic manic episode, 44 in euthymia for at least 6 months] and patients with Sch [41 with psychotic symptoms, 39 remitted according to Andreassen et al criteria (2006)] in comparison to 55 healthy controls (HC)

Read more

Summary

Methods

This was an observational, cross-sectional study of 243 male and female individuals between the ages of 12–26. The sample consists of participants in the Canadian Psychiatric Risk and Outcome Study (PROCAN) and included: asymptomatic participants at familial high risk for SMI (Stage 0; n=41); youth with early mood or anxiety symptoms (Stage 1a; n=52); youth with attenuated psychotic or affective syndromes and distress (Stages 1b; n=108); and HCs (n=42). Discussion: This study provides evidence for a growing literature which suggests that neurocognitive deficits may be markers of susceptibility for SMI development. It increases what is known about neurocognitive performance associated with different stages of risk for SMI. Identification of such impairments could aid with detection of early mental health problems prior to illness onset. Deniz Ceylan*,1, Berna Binnur Akdede, Emre Bora, Ceren Hıdıroğlu, Zeliha Tunca, Köksal Alptekin, Ayşegül Özerdem2 1Izmir University of Economics; 2Dokuz Eylül University, School of Medicine

Background
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call